---
document_datetime: 2023-09-21 19:41:10
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/macugen-epar-procedural-steps-taken-authorisation_en.pdf
document_name: macugen-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5658531
conversion_datetime: 2025-12-26 21:14:42.293295
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## 1 BACKGROUND INFORMATION ON THE PROCEDURE

## 1.1 Submission of the dossier

The applicant Pfizer Limited submitted on 31 August 2004 an application for Marketing Authorisation to the European Medicines Agency (EMEA) for Macugen, through the centralised procedure. The eligibility to the centralised procedure by the CHMP was agreed upon on 25 March 2004.

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were:

Rapporteur:

Bruno Flamion

Co-Rapporteur: Bengt Ljungberg

## Scientific Advice:

The applicant did not seek scientific advice at the CHMP. Licensing status: A new application is approved in the following countries: USA and Canada. 1.2 Steps taken for the assessment of the product · The application was received by the EMEA on 31 August 2004. · The procedure started on 20 September 2004. · The Rapporteur's first Assessment Report was circulated to all CHMP members on 6 December 2004.The Co-Rapporteur's first  Assessment  Report  was  circulated  to  all  CHMP  members  on  29 November 2004 · During  the  meeting  on  17-20  January  2005,  the  CHMP  agreed  on  the  consolidated  List  of Questions  to  be  sent  to  the  applicant.  The  final  consolidated  List  of  Questions  was  sent  to  the applicant on  20 January 2005 · The applicant submitted the responses to the CHMP consolidated List of Questions on 15 April 2005. · The summary report of the inspection carried out at the manufacturing Raylo Fine Chemicals site was signed by inspectors on 19 May 2005, and for the manufacturing Gilead Pharmaceuticals site was signed by the inspectors on 18 March 2005. · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on  31 May 2005 · During the CHMP meeting on 20-23 June 2005, the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant · A clarification meeting with the Rapporteur and Co-Rapporteur on the CHMP list of outstanding issues was held on 22 June 2005. · The applicant submitted the responses to the CHMP list of outstanding issues on 8 August 2005. Medicinal product no longer authorised

<!-- image -->

- The Rapporteurs circulated the updated Joint Assessment Report on the applicant's responses to the List of Outstanding Issues on 1 September 2005
- During  the  meeting  on    12-15  September  2005,  the  CHMP,  in  the  light  of  the  overall  data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to Macugen on 15 September 2005. The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 14 September 2005.
- On  28 November  2005  the EMEA  reviewed  spontaneous cases of anaphylactic eventshypersensitivity  notified  for  Macugen  and  in  consultation  with  the  rapporteur  requested  the applicant to provide a review of preclinical data, of all reported cases of anaphylactic events/hypersensitivity, and of relevant published literature, and to propose any measures necessary to address any safety concerns.
- On 2 December 2005 the applicant submitted a review document  together with supportive data. On 5 December 2005 the applicant submitted a proposal to revise the Annexes of the CHMP opinion of 15 September 2005.

<div style=\"page-break-after: always\"></div>

- The  Rapporteur's  Preliminary  Assessment  Report  was  circulated  to  the  CHMP  on  6  December 2005.
- On 6 December 2005 the EMEA informed the European Commission about the need for CHMP to assess new safety information for Macugen during the CHMP meeting of 12-15 December 2005.
- On 8 December 2005, the European Commission informed the EMEA that the preparation of a Commission  decision  on  the  basis  of  the  CHMP  opinion  of  15  September  2005  had  been suspended,  and  that  the  dossier  had  been  referred  back  to  the  EMEA  for  further  consideration during the CHMP meeting of 12-15 December 2005.
- The Rapporteur's Updated Assessment Report was circulated to the CHMP on 9 December 2005.
- During the meeting on 12-14 December 2005, in the light of the information submitted and the proposed  revisions  of  the  Summary  of  Product  Characteristics  and  Package  Leaflet,  the  CHMP adopted a revised opinion for granting a Marketing Authorisation for Macugen on 14 December 2005.
- The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the European Commission, which adopted the corresponding Decisions on 31 January 2006.

<!-- image -->

Medicinal product no longer authorised